UK Report Casts Doubt Over Use Of QALYs When Appraising Ultra Orphans
Executive Summary
Office of Health Economics suggests additional criteria could include social preferences on treating patients with very rare diseases, impact beyond direct health benefits, or adjustments for low patient numbers.
You may also be interested in...
NHS England/NICE Consultation Could Spell Market Access Complications
Companies with innovative and expensive drugs may face additional hurdles to get their products to the market in England, according to a consultation from NICE, England's health technology appraisal institute, and NHS England.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.